Logo image of DRMA

DERMATA THERAPEUTICS INC (DRMA) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:DRMA - US2498455045 - Common Stock

2.32 USD
+0.04 (+1.75%)
Last: 12/31/2025, 8:00:01 PM
2.22 USD
-0.1 (-4.31%)
After Hours: 12/31/2025, 8:00:01 PM
Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to DRMA. DRMA was compared to 530 industry peers in the Biotechnology industry. The financial health of DRMA is average, but there are quite some concerns on its profitability. DRMA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year DRMA has reported negative net income.
DRMA had a negative operating cash flow in the past year.
In the past 5 years DRMA always reported negative net income.
DRMA had a negative operating cash flow in each of the past 5 years.
DRMA Yearly Net Income VS EBIT VS OCF VS FCFDRMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

DRMA's Return On Assets of -174.46% is on the low side compared to the rest of the industry. DRMA is outperformed by 86.60% of its industry peers.
Looking at the Return On Equity, with a value of -223.42%, DRMA is doing worse than 69.62% of the companies in the same industry.
Industry RankSector Rank
ROA -174.46%
ROE -223.42%
ROIC N/A
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DRMA Yearly ROA, ROE, ROICDRMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K -1K 2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DRMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DRMA Yearly Profit, Operating, Gross MarginsDRMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

DRMA has more shares outstanding than it did 1 year ago.
DRMA has more shares outstanding than it did 5 years ago.
There is no outstanding debt for DRMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DRMA Yearly Shares OutstandingDRMA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 50K 100K 150K 200K 250K
DRMA Yearly Total Debt VS Total AssetsDRMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

DRMA has an Altman-Z score of -23.38. This is a bad value and indicates that DRMA is not financially healthy and even has some risk of bankruptcy.
DRMA has a worse Altman-Z score (-23.38) than 84.15% of its industry peers.
There is no outstanding debt for DRMA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -23.38
ROIC/WACCN/A
WACCN/A
DRMA Yearly LT Debt VS Equity VS FCFDRMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M

2.3 Liquidity

A Current Ratio of 4.56 indicates that DRMA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.56, DRMA is in line with its industry, outperforming 53.02% of the companies in the same industry.
A Quick Ratio of 4.56 indicates that DRMA has no problem at all paying its short term obligations.
The Quick ratio of DRMA (4.56) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.56
Quick Ratio 4.56
DRMA Yearly Current Assets VS Current LiabilitesDRMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 82.70% over the past year.
EPS 1Y (TTM)82.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.91%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DRMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.71% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.68%
EPS Next 2Y40.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DRMA Yearly EPS VS EstimatesDRMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -2K -4K -6K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DRMA. In the last year negative earnings were reported.
Also next year DRMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DRMA Price Earnings VS Forward Price EarningsDRMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DRMA Per share dataDRMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20

4.3 Compensation for Growth

A more expensive valuation may be justified as DRMA's earnings are expected to grow with 40.71% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.71%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DRMA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

DERMATA THERAPEUTICS INC

NASDAQ:DRMA (12/31/2025, 8:00:01 PM)

After market: 2.22 -0.1 (-4.31%)

2.32

+0.04 (+1.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-17 2026-03-17/amc
Inst Owners8.99%
Inst Owner ChangeN/A
Ins Owners3.5%
Ins Owner Change0%
Market Cap2.39M
Revenue(TTM)N/A
Net Income(TTM)-8.85M
Analysts82.86
Price Target10.2 (339.66%)
Short Float %4.32%
Short Ratio0.06
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.07%
Min EPS beat(2)-1.74%
Max EPS beat(2)43.88%
EPS beat(4)2
Avg EPS beat(4)2.37%
Min EPS beat(4)-34.64%
Max EPS beat(4)43.88%
EPS beat(8)4
Avg EPS beat(8)8.9%
EPS beat(12)8
Avg EPS beat(12)13.54%
EPS beat(16)12
Avg EPS beat(16)15.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-2.67%
EPS NQ rev (3m)-2.67%
EPS NY rev (1m)-3.09%
EPS NY rev (3m)-3.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.6
EV/EBITDA N/A
EPS(TTM)-28.41
EYN/A
EPS(NY)-3.07
Fwd EYN/A
FCF(TTM)-9.07
FCFYN/A
OCF(TTM)-9.07
OCFYN/A
SpS0
BVpS3.84
TBVpS3.84
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -174.46%
ROE -223.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-194.6%
ROA(5y)-241.76%
ROE(3y)-356.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.56
Quick Ratio 4.56
Altman-Z -23.38
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)82.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.91%
EPS Next Y94.68%
EPS Next 2Y40.71%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y21.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-31.82%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.82%
OCF growth 3YN/A
OCF growth 5YN/A

DERMATA THERAPEUTICS INC / DRMA FAQ

What is the ChartMill fundamental rating of DERMATA THERAPEUTICS INC (DRMA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to DRMA.


What is the valuation status for DRMA stock?

ChartMill assigns a valuation rating of 1 / 10 to DERMATA THERAPEUTICS INC (DRMA). This can be considered as Overvalued.


Can you provide the profitability details for DERMATA THERAPEUTICS INC?

DERMATA THERAPEUTICS INC (DRMA) has a profitability rating of 0 / 10.


Can you provide the financial health for DRMA stock?

The financial health rating of DERMATA THERAPEUTICS INC (DRMA) is 6 / 10.


Can you provide the expected EPS growth for DRMA stock?

The Earnings per Share (EPS) of DERMATA THERAPEUTICS INC (DRMA) is expected to grow by 94.68% in the next year.